To systematically evaluate the therapeutic effect of Shenling Baizhu Powder on blood glucose and related indexes in patients with type-2 diabetes and provide evidence for the extensive application of Shenling Baizhu Powder in patients with type-2 diabetes and its mechanism of action.Methods:Eight commonly used databases，including PubMed，Embase，Sinomed，Cochrane library，Web of Science，China national knowledge infrastructure(CNKI)，China science periodical database(CSPD)，and Chinese citation database(CCD)，were searched by computer.Randomized controlled trials(RCTs) of intervention effects of Shenling Baizhu Powder on patients with type-2 diabetes were retrieved from the establishment of these databases to April 20，2021.Literature screening，data extraction，quality evaluation，and risk assessment were conducted independently by two researchers according to inclusion and exclusion criteria.Meta-analysis was performed by using Review Manager 5.3 software.Results:A total of 143 relevant literature was searched，and 24 of them were included，involving a total of 2 131 patients.Meta-analysis showed that Shenling Baizhu Powder could reduce fasting blood glucose(FBG) in patients [weighted mean difference(MD)=-0.75，95% confidence interval(CI) -0.96 to -0.53，P<0.01] and 2-hour post-meal blood glucose(2 h PG)(MD -0.79，95%CI -1.22 to -0.35，P<0.01).It could also reduce glycosylated hemoglobin of patients(HbA1c)(MD -0.77，95%CI -0.95 to 0.60，P<0.01) and improve fasting insulin(FINS)(MD -4.641，95%CI -5.601 to -3.67，P<0.01).In addition，it significantly affected the insulin resistance index(MD -2.36，95%CI -2.60 to -2.11，P<0.01)，glucagon-like peptide-1(GLP-1)(MD 5.25，95%CI 4.80 to 5.70，P<0.01)，gastric inhibitory peptide(GIP)(MD 16.86，95%CI 14.27 to 19.45，P<0.01)，body weight(MD -4.45，95%CI -6.53 to -2.37，P<0.01)，and body mass index(MD -1.05，95%CI -1.76 to -0.33，P<0.01).Conclusion:This study suggests that Shenling Baizhu Powder has a hypoglycemic effect，which may be related to GIP，GLP-1，body weight，and increased serum insulin.